Updated Time: Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024 at 8:40 am ET
Rhea-AI Summary
Agios Pharmaceuticals (Nasdaq: AGIO) will present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024, at 8:40 a.m. ET. The company, known for its leadership in cellular metabolism and PK activation therapies for rare diseases, will provide a live webcast of the presentation, accessible via the 'Events & Presentations' section of its website. The webcast replay will be available on the company's site for two weeks.
Positive
- Agios Pharmaceuticals is participating in a high-profile event, potentially increasing visibility and investor interest.
- Live webcast accessibility allows broader audience engagement.
- Replay availability for two weeks ensures that stakeholders can view the presentation at their convenience.
Negative
- The announcement lacks specific details on potential new developments or data to be presented, which might not generate significant investor excitement.
News Market Reaction – AGIO
In the trading session that priced this news, AGIO declined 2.11%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that the time of the company’s presentation at the Goldman Sachs 45th Annual Global Healthcare Conference has been updated to Monday, June 10, 2024 at 8:40 a.m. ET.
A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. A replay of the webcast will be archived on the company’s website for at least two weeks following the presentation.
About Agios
Agios is the pioneering leader in PK activation and is dedicated to developing and delivering transformative therapies for patients living with rare diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company's deep scientific expertise in classical hematology and leadership in the field of cellular metabolism and rare hematologic diseases, Agios is advancing a robust clinical pipeline of investigational medicines with programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency, MDS-associated anemia and phenylketonuria (PKU). In addition to its clinical pipeline, Agios is advancing a preclinical TMPRSS6 siRNA as a potential treatment for polycythemia vera. For more information, please visit the company’s website at www.agios.com.
Contacts:
Investor Contact
Chris Taylor, VP, Investor Relations and Corporate Communications
Agios Pharmaceuticals
IR@agios.com
Media Contact
Dan Budwick
1AB
dan@1abmedia.com
